No change in apolipoprotein AI metabolism when subcutaneous insulin infusion is replaced by intraperitoneal insulin infusion in type 1 diabetic patients

Dyslipidemia in Type 1 Diabetes: A Masked Danger

“…After a switch from the usual subcutaneous insulin delivery to intraperitoneal insulin therapy which try to mimic the physiologic route of insulin delivery, an increase in plasma triglycerides was observed in one study but not in three others, total cholesterol and apoB were unchanged and HDL-cholesterol was decreased or stable (4). In vivo kinetic studies did not find significant changes in VLDL-apoB, LDL-apoB or HDL-A-I metabolism in T1D patients after subcutaneous insulin infusion was replaced by intraperitoneal insulin infusion (73,74). Thus, data from the literature show some discrepancies that may be due to confounding factors such as the degree of glycemic control and peripheral insulin levels during subcutaneous insulin therapy.…”

Lipid disorders in type 1 diabetes

“…Total cholesterol and apoB were found unchanged (Bagdade & Dunn, 1996;Ruotolo et al, 1994;Duvillard et al, 2005). HDL-cholesterol has been found decreased (Selam et al, 1989) or not modified (Bagdade & Dunn, 1996;Ruotolo et al, 1994;Duvillard et al, 2007). The discrepancies of these studies that may be due to confounding factors such as degree of glycemic control and peripheral insulin levels during subcutaneous insulin therapy.…”